FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Machinatan	D C	20540	
Nashington,	D.C.	20049	

STATEMENT	OF CHANG	ES IN BENE	FICIAL OW	NERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average bu	ırden									
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Rich Cadmus					2. Issuer Name and Ticker or Trading Symbol Aura Biosciences, Inc. [AURA]									all app Direc	o of Reportin licable) tor er (give title	ng Per	rson(s) to Is 10% O	wner	
	(Last) (First) (Middle) C/O AURA BIOSCIENCES, INC. 80 GUEST STREET						3. Date of Earliest Transaction (Month/Day/Year) 10/31/2022								below) below) See Remarks				
(Street) BOSTON (City)			123: Zip)	5	4. IT /	If Amendment, Date of Original Filed (Month/Day/Year)								ine)	ividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
		Table	I - I	Non-Deriva	tive S	Secur	ities	Acc	quire	ed, Di	sposed o	f, or E	Benefic	ially	Own	ed			
Date			2. Transaction Date (Month/Day/Ye	Execution Date,		T C			4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 ar			nd 5) Secur Benet		rities F ficially (I d Following Ir		wnership n: Direct or rect (I) tr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							c	Code V		Amount	(A) or (D)	Price		Transaction(s) (Instr. 3 and 4)			,	(
Common Stock 10/31			10/31/202	.2			S ⁽¹⁾		1,672	D	\$12.448	2.4481(2)		24,578		D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	ve Conversion or Exercise of Derivative Security Date (Month/Day/Year) Date (Month/Day/Year) Execution Date, if any (Month/Day/Year) Execution Date, if any (Month/Day/Year) Security		Transa Code (5. Nur of Deriva Secur Acqui (A) or Dispo of (D) (Instr. and 5	ative ities red sed 3, 4	6. Date Exercisable and Expiration Date (Month/Day/Year) Date Exercisable Expiration Date		Amo Secu Unde Deriv Secu 3 and	rlying ative rity (Instr.	nt er		9. Number derivative Securities Beneficially Owned Following Reported Transactior (Instr. 4)	,	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			

Explanation of Responses:

- 1. The sales reported represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1.
- 2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$12.40 to \$12.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

Chief Medical Officer, Head of R&D

/s/ Julie Feder, as Attorney-in-

11/02/2022

Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.